Pulmatrix Inc. | Mutual Funds
Mutual Funds that own Pulmatrix Inc.
Vanguard Extended Market Index Fund
415,907
0.89%
0
0%
07/31/2018
Vanguard Total Stock Market Index Fund
171,620
0.37%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
141,136
0.3%
0
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
100,000
0.21%
100,000
0.01%
12/31/2017
Vanguard Balanced Index Fund
64,946
0.14%
0
0%
07/31/2018
Fidelity Nasdaq Composite Index
49,084
0.11%
0
0%
07/31/2018
9,737
0.02%
0
0.01%
09/05/2018
AXA/Lord Abbett Micro Cap Portfolio
2,320
0.01%
0
0%
03/31/2018
iShares Core S&P Total US Stock Market ETF
155
0%
0
0%
09/06/2018
BlackRock (Japan) US Small Cap Growth Equity Open Mother Fund
0
0%
-1,572
0%
09/20/2016
| Address |
99 Hayden Avenue
Lexington Massachusetts 02421
United States
|
|
Employees
|
- |
| Website |
http://www.pulmatrix.com |
| Updated |
07/08/2019 |
| Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products. The company focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. |
